Neurocrine Biosciences Inc
Save
13.13B
Market cap
53.44x
Current P/E
30.12x
Forward P/E
About
Health care
Sector
Drug Manufacturers - Specialty & Generic
Industry
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia.
Similar securities
Based on sector and market capitalization
Report issue